The role of P-glycoprotein in the bioactivation of raloxifene

Drug Metabolism and Disposition

Volumn 34, Issue 12, 2006, Pages 2073-2078

  Chang, Jae H ^a   Kochansky, Christopher J ^a   Shou, Magang ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLPYRAZOLE; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; GLUTATHIONE; GLYCOPROTEIN P; KETOCONAZOLE; NAPHTHALENE; RALOXIFENE; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVATION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIVER CELL; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN FUNCTION;

BIOTRANSFORMATION; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; GLUTATHIONE; HEPATOCYTES; HUMANS; KETOCONAZOLE; MICROSOMES, LIVER; NAPHTHALENES; P-GLYCOPROTEIN; PYRAZOLES; RALOXIFENE; VERAPAMIL;

EID: 33751517109     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012179     Document Type: Article

References (33)

1. Benet LZ and Cummins CL (2001) The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 50 (Suppl 1):S3-S11.
2. Benet LZ, Cummins CL, and Wu CY (2003) Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4:393-398.
3. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, and Roninson IB (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389.
4. Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, Blizzard TA, Hammond ML, Stearns RA, Evans DC, et al. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15:907-914.
5. Choi K, Frommel TO, Stern RK, Perez CF, Kriegler M, Tsuruo T, and Roninson IB (1991) Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. Proc Natl Acad Sci USA 88:7386-7390.
6. Christensen CB and Jorgensen LN (1987) Morphine-6-glucuronide has high affinity for the opioid receptor. Pharmacol Toxicol 60:75-76.
7. Cummins CL, Jacobsen W, and Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
8. Day SH, Mao A, White R, Schulz-Utermoehl T, Miller R, and Beconi MG (2005) A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J Pharmacol Toxicol Methods 52:278-285.
9. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, et al. (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124.
10. Gram TE (1997) Chemically reactive intermediates and pulmonary xenobiotic toxicity. Pharmacol Rev 49:297-341.
11. Hardman J, Limbird L, and Gilman A (2001) Goodman & Gilman's The Pharmacological Basis of Therapeutics. The McGraw-Hill Company, Inc, New York.
12. Jeong EJ, Lin H, and Hu M (2004) Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J Pharmacol Exp Ther 310:376-385.
13. Jerina DM, Daly JW, Witkop B, Zaltzman-Nirenberg P, and Udenfriend S (1970) 1,2-Naphthalene oxide as an intermediate in the microsomal hydroxylation of naphthalene. Biochemistry 9:147-156.
14. Johnson BM, Charman WN, and Porter CJ (2003) Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. Drug Metab Dispos 31:1151-1160.
15. Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette JR, and Brodie BB (1973) Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther 187:195-202.
16. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
17. Kalgutkar AS and Nguyen HT (2004) Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event. Drug Metab Dispos 32:943-952.
18. Lee CG, Ramachandra M, Jeang KT, Martin MA, Pastan I, and Gottesman MM (2000) Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J 14:516-522.
19. Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, and Silber PM (1999) Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem-Biol Interact 121:17-35.
20. Loe DW, Deeley RG, and Cole SP (2000) Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 293:530-538.
21. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.
22. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, and Brodie BB (1973) Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther 187:185-194.
23. Oguri K, Yamada-Mori I, Shigezane J, Hirano T, and Yoshimura H (1987) Enhanced binding of morphine and nalorphine to opioid delta receptor by glucuronate and sulfate conjugations at the 6-position. Life Sci 41:1457-1464.
24. Potter WZ, Davis DC, Mitchell JR, Jollow DJ, Gillette JR, and Brodie BB (1973) Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther 187:203-210.
25. Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, and Sugiyama Y (2003) Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 18:33-41.
26. Silverman JA and Schrenk D (1997) Hepatic canalicular membrane 4: expression of the multidrug resistance genes in the liver. FASEB J 11:308-313.
27. Sohlenius-Sternbeck AK and Schmidt S (2005) Impaired glutathione- conjugating capacity by cryopreserved human and rat hepatocytes. Xenobiotica 35:727-736.
28. Tingle MD, Pirmohamed M, Templeton E, Wilson AS, Madden S, Kitteringham NR, and Park BK (1993) An investigation of the formation of cytotoxic, genotoxic, protein-reactive and stable metabolites from naphthalene by human liver microsomes. Biochem Pharmacol 46:1529-1538.
29. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, and DeVane CL (2004) Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl) 173:132-138.
30. Wilson AS, Davis CD, Williams DP, Buckpitt AR, Pirmohamed M, and Park BK (1996) Characterisation of the toxic metabolite(s) of naphthalene. Toxicology 114:233-242.
31. Xie R, Hammarlund-Udenaes M, de Boer AG, and de Lange EC (1999) The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol 128:563-568.
32. Yeo KR and Yeo WW (2001) Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 51:461-470.
33. Zhou S, Chan E, Duan W, Huang M, and Chen YZ (2005) Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 37:41-213.